Literature DB >> 3167844

Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.

C P Spears1, B G Gustavsson, M Berne, R Frösing, L Bernstein, A A Hayes.   

Abstract

Fifty-four patients with metastatic adenocarcinoma received i.v. bolus 5-fluorouracil, 500 mg/m2, prior to surgical biopsy of tumor at 20-400 min, for analysis of biochemical parameters of resistance to thymidylate synthase (TS) inhibition. The majority of patients, 37, had colon or rectal adenocarcinoma, five had breast cancer, five had gastric primary disease, four had pancreatic adenocarcinoma, and three had hepatocellular adenocarcinoma. Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate. Free levels of TS were lower in breast cancers, 0.08 +/- 0.06 pmol/g, than in other histologies (overall average, 1.41 +/- 2.25), associated with significantly greater percentages of TS inhibition (88.6% versus 62.0% overall). Colorectal tumors showed significantly greater FdUMP levels than other gastrointestinal malignancies, associated with somewhat lower free TS values. Plots of FdUMP levels, or (FdUMP/dUMP) x 100 values versus percentages of TS inhibition suggested minima of 75 pmol/g and 0.10, respectively, for achieving maximal enzyme inhibition. Analyses of normal tissues showed: poor TS inhibition in liver and normal colonic mucosa, related to low FdUMP levels; and very high dUMP levels in bone marrow leukocytes suggestive of reactive increases in dUMP as an important mechanism of recovery in this tissue. Among the 30 of the 37 colorectal tumors that showed suboptimal (less than 85%) inhibition of TS, 16 (53%) showed FdUMP levels less than 75 pmol/g, 8 (27%) showed relatively high dUMP levels (over 35 nmol/g), and 16 (53%) showed poor efficiency of inhibition of TS, with the major overlap between these mechanisms of resistance being high dUMP and poor binding in 6 (20%). These data provide a strong rationale for administration of leucovorin to the majority of patients receiving 5-fluorouracil, since increased intratumoral reduced folates potentially can overcome multiple mechanisms of resistance including low FdUMP, high dUMP, and high total TS levels, in addition to that caused by isolated folate deficiency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167844

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

Authors:  Ellen J B Derissen; Bart A W Jacobs; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2016-03-02       Impact factor: 4.335

Review 2.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.

Authors:  Hiroaki Tsujimoto; Sayaka Tsukioka; Satoru Ono; Etsuko Sakamoto; Kazuki Sakamoto; Kohji Tsuta; Fumio Nakagawa; Hitoshi Saito; Junji Uchida; Mamoru Kiniwa; Masakazu Fukushima
Journal:  Oncol Lett       Date:  2010-09-17       Impact factor: 2.967

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin.

Authors:  K Omura; T Misaki; T Hashimoto; E Kanehira; T Watanabe; F Ishida; Y Watanabe; T Shirasaka
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.

Authors:  Toshihiro Komura; Koh Miura; Tetsuhiko Shirasaka; Shinobu Ohnuma; Miki Shimada; Taiki Kajiwara; Fumiyoshi Fujishima; Alex Philchenkov; Kei Nakagawa; Katsuyoshi Kudoh; Sho Haneda; Masahide Toshima; Atsushi Kohyama; Hiroaki Musha; Takeshi Naitoh; Chikashi Shibata; Michiaki Unno
Journal:  Int J Clin Oncol       Date:  2014-05-08       Impact factor: 3.402

7.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer.

Authors:  H Nakano; K Namatame; T Suzuki; H Takahashi; H Sakai; T Nakamura; K Kumada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

10.  Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.

Authors:  Jing Li; Seongho Kim; Anthony F Shields; Kirk A Douglas; Christopher I McHugh; Jawana M Lawhorn-Crews; Jianmei Wu; Thomas J Mangner; Patricia M LoRusso
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.